Overview
- Lilly agreed to buy AtaiBeckley for about $2.8 billion in cash, with additional milestone payments possible depending on clinical and regulatory progress.
- AtaiBeckley’s lead candidate, BPL‑003, is an investigational therapy for treatment‑resistant depression that posted strong phase 2 results and will now join Lilly’s neuroscience portfolio.
- The acquisition follows Lilly’s larger purchase of Centessa in June, which added cleminorexton, an agent being studied for narcolepsy and idiopathic hypersomnia.
- Lilly’s ability to fund large cash deals is underpinned by heavy Zepbound sales in the obesity and diabetes market, which analysts say helps the company hedge against future GLP‑1 competition.
- The strategy shifts capital into high‑need areas like mental health and sleep disorders but carries development risk because future payments and clinical success are not guaranteed.